Paxlovid™ (Nirmatrelvir (PF-07321332))/Ritonavir)

What are the ingredients in Paxlovid?

Nirmatrelvir

Tablet core: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal silicon dioxide, sodium stearyl fumarate. Film-coat:hydroxy propyl methylcellulose (E464), titanium dioxide (E171), polyethylene glycol (E1521), iron oxide red (E172).

Ritonavir

Tablet core: copovidone, sorbitan laureate, silica, colloidal anhydrous, calcium hydrogen phosphate, anhydrous, sodium stearyl fumarate. Film-coat: hypromellose (E464), titanium dioxide (E171), macrogol, hydroxypropyl cellulose (E463), talc (E553b), silica, colloidal anhydrous (E551), polysorbate 80 (E433).

For information regarding other allergen/ingredients, please contact Medical Information at www.pfizermedicalinformationgulf.com or contact our Medical Information team on contact us.

Does Paxlovid contain lactose?

Each Nirmatrelvir 150 mg film-coated tablet contains 176 mg of lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

We cannot guarantee that minute amounts of substances are not contained in raw materials obtained from our suppliers. To ensure we have a consistent and reliable supply of medications, we must use a network of suppliers and manufacturing sites globally for both active and inactive ingredients.

For information regarding other allergen/ingredients, please contact Medical Information at www.pfizermedicalinformationgulf.com or contact our Medical Information team on contact us.

Does Paxlovid contain sodium?

Nirmatrelvir and ritonavir each contain less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium free’.

We cannot guarantee that minute amounts of substances are not contained in raw materials obtained from our suppliers. To ensure we have a consistent and reliable supply of medications, we must use a network of suppliers and manufacturing sites globally for both active and inactive ingredients.

For information regarding other allergen/ingredients, please contact Medical Information at www.pfizermedicalinformationgulf.com or contact our Medical Information team on contact us.

Ritonavir is administered with PF-07321332 as a pharmacokinetic enhancer resulting in higher systemic concentrations of PF-07321332.

Ritonavir is not active against the SARS-CoV-2 3CL protease. Ritonavir inhibits the CYP3A-mediated metabolism of PF-07321332, thereby providing increased plasma concentrations of PF-07321332.

In healthy participants, the mean half-life of a single dose of 150 mg PF‑07321332 administered alone was approximately 2 hours compared to 7.5 hours after administration of a single dose of 250 mg/100 mg dose of PF-07321332/ritonavir thereby supporting a twice‑daily administration regimen.

View Paxlovid™ (Nirmatrelvir (PF-07321332))/Ritonavir) Summary of Product Characteristics